Urges Senate HELP Committee to Include ‘Real’  Biogenerics Legislation as Part of Health Reform

(Washington, DC)- The Pharmaceutical Care Management Association (PCMA) today launched a new ad campaign urging members of the U.S. Senate Health, Education, Labor, and Pensions (HELP) committee to include meaningful biogenerics legislation as a means to improve and finance broader health reform efforts.  PCMA President and CEO Mark Merritt issued the following statement:

“If this week’s report is accurate that Washington and the drug company lobby have reached some kind of new health reform ‘agreement,’ we sincerely hope that biogenerics is not part of it.  The drug lobby will truly have reason to celebrate if Washington either ignores biogenerics reform or, worse, establishes a new process that could actually forbid competition for years after patents expire.  

“Either outcome would mean sky-rocketing costs for seniors in the donut hole, taxpayers, employers, and patients who desperately need access to these expensive, life-saving medications.”

###